Literature DB >> 24764663

Interval to surgery after neoadjuvant treatment for colorectal cancer.

Nir Wasserberg1.   

Abstract

The current standard treatment of low-lying locally advanced rectal cancer consists of chemoradiation followed by radical surgery. The interval between chemoradiation and surgery varied for many years until the 1999 Lyon R90-01 trial which compared the effects of a short (2-wk) and long (6-wk) interval. Results showed a better clinical tumor response (71.7% vs 53.1%) and higher rate of positive and pathologic tumor regression (26% vs 10.3%) after the longer interval. Accordingly, a 6-wk interval between chemoradiation and surgery was set to balance the oncological results with the surgical complexity. However, several recent retrospective studies reported that prolonging the interval beyond 8 or even 12 wk may lead to significantly higher rates of tumor downstaging and pathologic complete response. This in turn, according to some reports, may improve overall and disease-free survival, without increasing the surgical difficulty or complications. This work reviews the data on the effect of different intervals, derived mostly from retrospective analyses using a wide variation of treatment protocols. Prospective randomized trials are currently ongoing.

Entities:  

Keywords:  Chemoradiation therapy; Colorectal cancer; Interval to surgery; Neoadjuvant; Rectal cancer; Surgery

Mesh:

Year:  2014        PMID: 24764663      PMCID: PMC3989961          DOI: 10.3748/wjg.v20.i15.4256

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  64 in total

1.  Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Authors:  Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-11       Impact factor: 7.038

2.  Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial.

Authors:  L Påhlman; B Glimelius
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

3.  Preoperative irradiation of rectosigmoid carcinoma including its regional lymph nodes.

Authors:  M M Kligerman; N Urdaneta; A Knowlton; R Vidone; P V Hartman; R Vera
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1972-03

4.  Oncologic outcomes of primary and post-irradiated early stage rectal cancer: a retrospective cohort study.

Authors:  Chang-Zheng Du; Yong-Chun Chen; Yong Cai; Wei-Cheng Xue; Jin Gu
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

5.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

6.  Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study.

Authors:  Stephane Supiot; Wilfried Gouraud; Loïc Campion; Pascal Jezéquel; Bruno Buecher; Josiane Charrier; Marie-Francoise Heymann; Marc-Andre Mahé; Emmanuel Rio; Michel Chérel
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

7.  Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.

Authors:  D A M Sloothaak; D E Geijsen; N J van Leersum; C J A Punt; C J Buskens; W A Bemelman; P J Tanis
Journal:  Br J Surg       Date:  2013-03-27       Impact factor: 6.939

8.  Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

Review 9.  Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature.

Authors:  Jake D Foster; Emma L Jones; Stephen Falk; Edwin J Cooper; Nader K Francis
Journal:  Dis Colon Rectum       Date:  2013-07       Impact factor: 4.585

10.  Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.

Authors:  C M Dolinsky; N N Mahmoud; R Mick; W Sun; R W Whittington; L J Solin; D G Haller; B J Giantonio; P J O'Dwyer; E F Rosato; R D Fry; J M Metz
Journal:  J Surg Oncol       Date:  2007-09-01       Impact factor: 3.454

View more
  18 in total

1.  Optimal interval of surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: population level evidence in addition to controlled trial.

Authors:  William Tzu-Liang Chen; Tao-Wei Ke; Yu-Min Liao; Chia-Chin Li; Chun-Ru Chien
Journal:  J Gastrointest Oncol       Date:  2015-06

2.  Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.

Authors:  Erhan Akgun; Cemil Caliskan; Osman Bozbiyik; Tayfun Yoldas; Basak Doganavsargil; Serdar Ozkok; Timur Kose; Bulent Karabulut; Nevra Elmas; Omer Ozutemiz
Journal:  BJS Open       Date:  2022-09-02

3.  Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms.

Authors:  Aeris Jane D Nacion; Youn Young Park; Nam Kyu Kim
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

4.  Physical activity levels in locally advanced rectal cancer patients following neoadjuvant chemoradiotherapy and an exercise training programme before surgery: a pilot study.

Authors:  Lisa Loughney; Malcolm A West; Borislav D Dimitrov; Graham J Kemp; Michael Pw Grocott; Sandy Jack
Journal:  Perioper Med (Lond)       Date:  2017-02-16

5.  MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma.

Authors:  Cory Pettit; Amy Webb; Steve Walston; Moumita Chatterjee; Wei Chen; Wendy Frankel; Carlo Croce; Terence M Williams
Journal:  Oncotarget       Date:  2018-06-22

6.  Pathological Complete Response After Neoadjuvant Therapy in Rectal Adenocarcinoma: a 5-Year Follow-up.

Authors:  Yeen Chin Leow; April Camilla Roslani; Ruben Gregory Xavier; Fei Yee Lee
Journal:  Indian J Surg       Date:  2021-05-27       Impact factor: 0.656

7.  The effects of neoadjuvant chemoradiotherapy and an in-hospital exercise training programme on physical fitness and quality of life in locally advanced rectal cancer patients (The EMPOWER Trial): study protocol for a randomised controlled trial.

Authors:  Lisa Loughney; Malcolm A West; Graham J Kemp; Harry B Rossiter; Shaunna M Burke; Trevor Cox; Christopher P Barben; Michael G Mythen; Peter Calverley; Daniel H Palmer; Michael P W Grocott; Sandy Jack
Journal:  Trials       Date:  2016-01-13       Impact factor: 2.279

8.  Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer.

Authors:  Daniela Rega; Biagio Pecori; Dario Scala; Antonio Avallone; Ugo Pace; Antonella Petrillo; Luigi Aloj; Fabiana Tatangelo; Paolo Delrio
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

9.  Treatment Interval between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer Patients: A Population-Based Study.

Authors:  A J M Rombouts; N Hugen; M A G Elferink; I D Nagtegaal; J H W de Wilt
Journal:  Ann Surg Oncol       Date:  2016-06-01       Impact factor: 5.344

10.  High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.

Authors:  Te-Min Ke; Li-Ching Lin; Chun-Che Huang; Yu-Wen Chien; Wei-Chen Ting; Ching-Chieh Yang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.